Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Walter Coats

Cardiovascular Disease Jefferson City, MO Doctor of Osteopathy

NPI 1316122245 CMS profile 59688

3501 W Truman Blvd # A, Jefferson City, MO 65109

Open in the dashboard

General payments

$1,991

47 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Walter Coats of Jefferson City, MO is reported in the CMS Open Payments database as having received $1,991 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $989 14
2024 General $514 12
2023 General $297 11
2022 General $26 2
2020 General $59 3
2019 General $105 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Walter Coats
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Walter Coats were reported at $989. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Walter Coats Cardiovascular Disease median Middle half National median
2019 $105 $450 $127–$1,392 $163
2020 $59 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $26 $395 $121–$1,211 $149
2023 $297 $443 $136–$1,283 $160
2024 $514 $450 $136–$1,323 $164
2025 $989 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $801 9 payments
  2. Boston Scientific Corporation $487 12 payments
  3. Shockwave Medical, Inc $246 5 payments
  4. Abbott Laboratories $117 6 payments
  5. Amgen Inc. $99 3 payments
  6. Janssen Pharmaceuticals, Inc $59 2 payments
  7. Novartis Pharmaceuticals Corporation $57 3 payments
  8. Medtronic, Inc. $56 3 payments
  9. Ge Healthcare $52 2 payments
  10. Regeneron Healthcare Solutions, Inc. $12 1 payment
  11. Other $5 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,592 43 payments
  2. Travel and Lodging $386 3 payments
  3. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $153 1 payment
  2. AVVIGO Guidance System $150 3 payments
  3. Impella $133 2 payments
  4. Repatha $99 3 payments
  5. General - Balloon Catheters $93 2 payments
  6. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $93 4 payments
  7. XARELTO $59 2 payments
  8. LEQVIO $57 3 payments
  9. ROTAPRO $43 2 payments
  10. LUX-Dx Insertable Cardiac Monitor $25 1 payment
  11. Other $208 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

9,114

Median for Interventional Cardiology: 2,236

Drug cost

$1,456,647

Median for Interventional Cardiology: $380,412

Branded share of claims

28.7%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 627 $656,382
Xarelto Rivaroxaban Brand 263 $323,306
Repatha Sureclick Evolocumab Brand 171 $192,531
Entresto Sacubitril/Valsartan Brand 105 $121,693
Praluent Pen Alirocumab Brand 56 $44,646
Atorvastatin Calcium Generic 867 $10,049
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 296 $8,588
Sotalol Sotalol Hcl Brand 395 $8,164
Amiodarone Hcl Generic 184 $7,150
Metoprolol Succinate Generic 370 $6,640

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$261,656

Of which drugs: $1,929

Medicare patients

1,383

Average age 77

Services billed

3,830

701 women, 682 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 48%
Atrial fibrillation 43%
Diabetes 36%
Heart failure 32%
Chronic kidney disease 30%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 46 184 $1,379

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $60
$60 171 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record